bluebird bio (NASDAQ:BLUE) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a report issued on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Several other equities analysts have also weighed in on BLUE. Bank of America reduced their price objective on shares of bluebird bio from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Thursday, August 15th. Robert W. Baird reduced their price objective on bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 target price on shares of bluebird bio in a research report on Thursday, August 15th. Barclays decreased their price target on bluebird bio from $8.00 to $4.00 and set an “overweight” rating for the company in a research report on Thursday, August 15th. Finally, JPMorgan Chase & Co. downgraded bluebird bio from an “overweight” rating to a “neutral” rating in a report on Thursday, August 15th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $4.63.

bluebird bio Price Performance

NASDAQ BLUE opened at $0.48 on Thursday. The company has a 50-day moving average price of $0.60 and a two-hundred day moving average price of $0.88. bluebird bio has a 52 week low of $0.45 and a 52 week high of $5.53. The stock has a market cap of $52.68 million, a price-to-earnings ratio of -0.65 and a beta of 0.75. The company has a current ratio of 0.68, a quick ratio of 0.57 and a debt-to-equity ratio of 0.37.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. The business had revenue of $18.57 million during the quarter. bluebird bio had a negative return on equity of 207.25% and a negative net margin of 567.29%. Analysts forecast that bluebird bio will post -1.42 EPS for the current year.

Hedge Funds Weigh In On bluebird bio

Several institutional investors and hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its position in bluebird bio by 38.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company’s stock valued at $416,000 after purchasing an additional 90,139 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of bluebird bio during the 4th quarter valued at about $317,000. Vanguard Group Inc. grew its stake in shares of bluebird bio by 19.6% in the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock valued at $13,438,000 after buying an additional 1,723,081 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in bluebird bio by 113.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock worth $71,000 after buying an additional 29,113 shares during the last quarter. Finally, American International Group Inc. raised its position in bluebird bio by 77.4% during the first quarter. American International Group Inc. now owns 94,371 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 41,177 shares in the last quarter. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.